Leta i den här bloggen


torsdag 9 juli 2020

"BROMODOMEENI" esiintyy joissain proteiineissa.

Ensiksi näin maininnan proteiinin bromodomeenista TIRMproteiinisa  TRIM28 ( KAP1).
Toiseksi siitä mainittiin eräässä väitöstyössä,  onkologian alueella. ja siitä kirjoitan tässä enemmän. kolamnneksio  taas näin  täsä domeenista uudessa immuniteettia kåäsitelevässä kirjassa kirjastossa maintiavan  BET bromodomeenista   parilla lauseella.  Nyt siten huomaan SARS2 viruksen interaktioproteiinien jouksosa kaksi bromodomeenin omaavaa proteiinia BRD2 ja BRD4.
 Katson niistäkin  geeneistä tiedet  tämän teesikommentin jälkeen. Löytyy aika tuore artikkeli ja otan sen seuraavan otsikon alle.


Vuonna 2016 oli väitöstilaisuus ahlgrenskan akatemiassa  aiheesta "Targeting Myc-driven tumours  BETing on ATR. " Yleensä  en niin  ensisijaisesti mennyt onkologisia aiheita kuutnelemaan, muta tässä oli tuo MYC, josta  yritin saada käsitystä.
 Tässä sitten esiintyi se BET bromodomeeni ja HDAC inhibiittorit.    (Sirtuiinit olenkin katsonut  läpi ja tehnyt niistä muistiinpanpot )

Asetan  teesin tiedot tähän: http://hdl.handle.net/2077/41548
Osatyöt:

 Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, Hansen HC, Keller UB, McLure KG, Nilsson JA.
BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proceedings of the National Academy of Sciences. 2014 Jul 1;111(26):E2721-30
VISA ARTIKEL


II. Muralidharan SV, Bhadury J, Nilsson LM, Green LC, McLure KG, Nilsson JA.
 BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells. Oncogene. 2016 Jan 25
VISA ARTIKEL


III.“Synergistic enhancement of apoptosis in melanoma by ATR & BET bromodomain inhibitors”. Somsundar Veppil Muralidharan, Berglind Einarsdottir, Mattias Lindberg, Joydeep Bhadury, Eric Campeau, Roger Olofsson Bagge, Ulrika Stierner, Lars Ny, Lisa M. Nilsson and Jonas A. Nilsson (MANUSCRIPT).

Cancer arises from loss of function of tumour suppressors and/or gain of function mutations in proto-oncogenes that disrupt the delicate balance required for homeostatic cell division, resulting in uncontrolled cell proliferation. 
Oncogenic transformation of multifaceted proto-oncogene - transcription factor - MYC can give rise to cancers and it is found to be deregulated in more than 70% of the tumours
Targeting MYC directly or identifying the Achille’s heel of MYC-driven tumours is thus a promising therapeutic approach to treat these tumours.

 This thesis investigates and demonstrates novel therapeutic approaches against MYC-driven tumours.
 In the first publication (Bhadury et al, 2014), we characterize a novel and orally bio-available BET bromodomain inhibitor (BETi) RVX2135. 
We also identified BET bromodomain proteins as a valuable therapeutic target against MYC driven tumours in vitro and in vivo.
 Gene expression profiling to identify these transcriptional changes enabled us to identify subset of genes that are commonly altered by both BETi and HDACi. 

This study also demonstrates that HDACi and BETi can synergize to hinder Myc-induced lymphoma progression.

 The second publication (Muralidharan et al, 2016) in this thesis investigates the role of BET proteins in regulating cell cycle and replication. 
 BETi disable the entry of cells into S-phase of cell-cycle, hamper DNA synthesis and cause DNA damage.
 A pharmacogenetic screen identified BET inhibitors to synergize with inhibition of PI3K/mTOR family of proteins, to which ATR, an upstream kinase of DDR pathway belongs.
 Further studies revealed that the thus identified PI3K/mTOR inhibitors indeed affect ATR-Chkl DDR pathway leading to the discovery of a strong synergy between BETi and ATRi in apoptosing Myc driven tumours in vitro, and in vivo and (by) it induces SASP and ER stress. 

The third study translates the above findings into the field of melanoma, a form of skin cancer. We validate the BETi-ATRi synergy in cell lines in vitro and in Patient Derived Xenografts (PDX) in vivo.
 Using B16F10 in vivo syngenic transplant melanoma model, we also demonstrated that this combination therapy can be safely combined with Immune Therapy, the front line treatment against melanoma in clinic today. 
Taken together, this thesis puts forth a multifaceted approach to treat cancer. It thoroughly describes the effects of BETi and ATRi on cancer cells and how they can be combined to enhance the therapeutic efficacy

onsdag 8 juli 2020

RNA Pol II, P-TEFb

 (Otin sitaatin tästä artikkelista, koska siinä oli useita SARS 2 koronaviruksen interaktioproteiineiksi mainittuja proteiineja ja merkitsin ne tähdellä:* LARP7, MEPCE, BRD4, DDX21. Olen tänään katsomassa ribosomiin ja nukleoliin  kuuluvia proteiineja ja  tässä yhteydessä  näin  myös  7SK snoRNA- proteiinin ja sen funktiokaavoja, joissa oli  SARS2- interaktioproteiineja). 
 https://www.tandfonline.com/doi/pdf/10.1080/21541264.2017.1281864

POINT-OF-VIEW
 P-TEFb: Finding its ways to release promoter-proximally paused RNA polymerase II 


You Lia, Min Liua, Lin-Feng Chenb, and Ruichuan ChenaaState Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, China;bDepartment of Biochemistry, Collegeof Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, USA 

ARTICLE HISTORY 
Received 5 December 2016
 Revised 9 January 2017 Accepted 9 January 2017
 ABSTRACT 
The release of a paused Pol II depends on the recruitment of P-TEFb. Recent studies showed that both active P-TEFb and inactive P-TEFb (7SK snRNP) can be recruited to the promoter regions of global genes by different mechanisms. Here, we summarize the recent advances on these distinct recruitment mechanisms. 

KEYWORDS7SK snRNP; Brd4; KAP1;promoter-proximal pausing;P-TEFb; RNA Pol II; SEC;transcription elongation

 Introduction 
The eukaryotic transcription by RNA polymerase II(Pol II) involves several tightly co-ordinated steps.While the regulation of transcription initiation has  been a long-held paradigm, the transcription elonga-ion is recently regarded as another critical step for governing the expression of inducible genes.1-3Asearly as 1992, the in vitro transcription assay revealedthe existence of both positive and negative transcrip-tion elongation factors.4The factor with the capacity to promote transcription elongation was later characterized as 
P-TEFb (positive transcription elongationfactor b), a heterodimer kinase composed of CDK9 and its cyclin partner (primarily Cyclin T1 and T2).5
 The factors with negative role in elongation were identified as
 DSIF (DRB sensitivity-inducing factor, composed of Spt4 and Spt5) and 
NELF (negative elongation factor, composed of NELF-A, B, C/D, Esubunits).6,7 

Shortly after transcription initiation , DSIF and NELF bind to the initiated Pol II at the promoter-proximal region, 2060 n ucleotides down-stream of transcription start site, inducing the promoter-proximal pausing of Pol II.8,9 
Of importance, growing evidence has indicated that this pausing is a checkpoint for governing the quick expression of 3070% of the transcriptionally active genes in metazoans.2,3,10 
The release of paused Pol II depends on the recruitment of P-TEFb to promoter regions, where P-TEFb phosphorylates DSIF, NELF and the Ser2 of Pol II C-terminal domain (CTD).These P-TEFb-mediated phosphorylation events lead to the eviction of NELF from paused Pol II and the transition of Pol II from pausing into productive elongation, thereby allowing cells to rapidly and efficiently cope with various challenges.1,3,8,11 
The molecular mechanism that regulates the activity and recruitment of P-TEFb has been a field of interest to many researchers in the beginning of this century. Fifteen yearsefforts on this field have drawn out a sketch depicting how the activity and recruitment of P-TEFb is tightly regulated. In cells, the majority of P-TEFb is sequestrated in an inactive 7SK snRNP complex that contains 7SK snRNA 
and three nuclear proteins  
HEXIM1 (Hexamethylene Bis aceta-mide Inducible 1),  
MePCE* (Methylphosphate Cap-ping Enzyme)  (Comment: Sars 2  envelope interaction protein)
 and LARP7* (La Ribonucleoprotein Domain Family Member 7) (Comment: SARS2 nsp8 interaction protein)
Within this complex,MePCE and LARP7 bind to 7SK and stabilize 7SK
RNA, whereas 7SK serves as a scaffold to mediate theinteraction between HEXIM1 and P-TEFb, thereby maintaining P-TEFb in an inactive state.11-13

 Upon stress, the core P-TEFb is released from 7SK snRNP and is recruited to the target promoters via the P-TEFb recruitment factors.11,12,14,15Ample evidence indicates that the bromodomain-containing protein Brd4 and the super elongation complex SEC are capable of recruiting active P-TEFb to promoters.11,16-18
 Brd4*belongs to BET family that contains two bromodomains and an extraterminal domain. (Comment: Sars 2 virus Envelope protein  interaction protein )
 Upon stimula-tion, Brd4 binds to and recruits active P-TEFb topromoter regions to release paused Pol II.14,16,19-21
 SEC is a multi-subunit complex consisting one of four AFF scaffold proteins (AFF1 to AFF4), one of three ELL proteins (ELL1 to ELL3) and an ENL (or its analogue AF9).18 Similar to Brd4, SEC is able to interact with and recruit active P-TEFb to promoters for the release of paused Pol II.11,16-18 

Of interest, while the active P-TEFb has been proposed to be the major form that is inducibly recruited to gene promoters upon stimulation, several recent studies showed that the inactive P-TEFb in the 7SKsnRNA complex can also be loaded onto a vast array of promoters for the release of paused Pol II either in basal or stimulation state.22-24 
Although the recruitment of inactive 7SK snRNP and the release of P-TEFb at promoter employ very diverse mechanisms, nevertheless, it represents another approach to release the promoter-proximally paused Pol II. To distinguish these two distinct recruitment mechanisms, we referto the recruitment of active form of P-TEFb as the canonical P-TEFb recruitment model and the recruitment of inactive P-TEFb in complex with 7SK snRNPas the non-canonical P-TEFb recruitment model. In this short review, we summarize recent advances in dissecting these two kinds of recruitment models. 


The canonical P-TEFb recruitment model 
Ample evidence indicates that in metazoans, the promoter-proximal pausing of Pol II serves as a key step for controlling the expression of inducible genes that are critical for cell proliferation, differentiation and environment response. Although this pausing allows fast response in gene expression,3 the danger, how-ever, is that mistakes in releasing the paused Pol II may doom the fate of the cell beyond return. Hence,the release of paused Pol II must be tightly controlled. To achieve this, the release of P-TEFb from 7SKsnRNP, the availability of Brd4 and SEC and the recruitment of P-TEFb must be co-ordinated andstrictly regulated. For P-TEFb release, as revealed in our previousstudies,15,21  stress (such as UV, DOX and HMBA),induces the activation of protein phosphatase PP2B and PP1a signal pathways and these two pathways work together to open thelockthat detains P-TEFb in the inactive 7SK snRNP.12,13

 In this process, stress-activated PP2B actsfirst to induce the conformational change of nucleoplasmic 7SK snRNP complex to expose the concealed T-loop of Cdk9. This enables PP1a to access and dephosphorylate the T186ph of Cdk9 T-loop, leading to the release of P-TEFb from 7SK snRNP (Fig. 1A).15 Meanwhile, to release the chromatin-bound Brd4, stress-activated histone deacetylases HDAC1/2/3 work together with PP1a pathway to open anotherlockthat sequesters almost all of Brd4 on chromatin in unstimulated state.20,21  In this case, PP1a actsfirst to dephosphor-ylate the phospho-Ser10 of nucleosomal histone H3(H3S10ph). This allows HDACs to access to and deacetylate the acetylated K5 and K8 of nucleosomal H4 (H4K5ac/K8ac), thereby releasing the chromatin-bound Brd4 to recruit the active P-TEFb.20,21  

More-over, with a shared PP1a signal pathway, stress can induce the release of P-TEFb from 7SK snRNP and the release of chromatin-bound Brd4 at the same time and co-ordinate the recruitment of active P-TEFb simultaneously (Fig. 1A).15,21

 Moreover, even for the pause release, our most recent study revealed that Brd4 and SEC also work together to release a promoter-proximally paused PolII by recruiting multiple P-TEFbs (Fig. 1B).16 In thisprocess, the Mediator subunits (Med1 and Med23)and the transcription factor Tat-SF1 constitute a Brd4-P-TEFb complex-specific recruitment pathway. Upon stress, Brd4 delivers thefirst P-TEFb to DSIF via the recruitment pathway, leading to the phosphor-ylation of Spt5 subunit of DSIF. Meanwhile, AFF1-SEC/AFF4-SEC recruits the second P-TEFb to NELF-E via Med26, and AFF1-ENL-SEC/AFF1-AF9-SEC  recruits the third P-TEFb to NELF-A via Paf1c, leading to the phosphorylation of NELF-E and -A. These three phosphorylation events result in the eviction of NELF from paused Pol II and the release of Pol II into gene body. Then, AFF4-ENL-SEC/AFF4-AF9-SEC brings the forth P-TEFb to Paf1c to phosphorylate Pol
 I CTD at Ser2, which facilitates the 30-end processingof mRNA. The pause release is regulated by the co-operation of multiple P-TEFbs, which are recruited byBrd4 and SEC subtypes via a Mediator- and Paf1c-coordinated recruitment network (Fig. 1B).16 

Therefore, the canonical P-TEFb recruitment model at least involves the following steps: the release of P-TEFb from 7SK snRNP, the release of chromatin-bound Brd4 and the recruitment of multiple P-TEFbs by Brd4 and SEC. Each step is tightly controlled by at least two signal pathways so that to prevent the inappropriate release of the paused Pol II(Fig. 1). 

Of note, our previous data implicated that most of SECs components might associate with chromatin in unstimulated cells, and may need to be released as free form upon stress,16 suggesting the existence of a yet-to-be-identified step of signal-induced release of chromatin-associated SECcomponents. 

The non-canonical P-TEFb recruitment model 
Comparing to the canonical model, the non-canonicalP-TEFb recruitment model involves the recruitmentof 7SK snRNP and the release of P-TEFb at promoter (on site) (Fig. 2). The association of 7SK snRNP with HIV promoters was firstly reported in 2010 by DOrsoet al.25Most recently, DOrsos Lab demonstrated that transcriptional regulator KAP1 (also known asTrim28 and TF1b) was able to interact with LARP7
 and tether 7SK snRNP to the promoters of primary response genes (PRGs) in respond to stimuli.23,24 

Genome-wide studies showed that KAP1 and 7SK snRNP co-localized on most promoters containing paused Pol II.23 
Depletion of KAP1 reduced the promoter occupancy of 7SK snRNP and impeded the transcription elongation.24
 However, how P-TEFb is released from 7SK snRNP on-sitein this case remains unknown. Interestingly, in 2013, Fus Lab found that SR-splicing factor SRSF2 (also known as SC35) was able to interact with both 7SK RNA and promoter-associated nascent RNA and was recruited to promoter as a component of 7SK snRNP complex.26 
High-throughput ChIP-Seq analysis showed that SRSF2 could be loaded on promoter regions of a vast array of genes. Through the interaction between SRSF2 and exonic-splicing enhancer (ESE) RNA, ESE RNA co-ordinated the release of SRSF2 and the release of P-TEFb from the7SK snRNP at promoter, thereby leading to the transcription activation.26 

Meanwhile, Rosenfelds lab identified that the recruitment of Brd4-dependent demethylase JMJD6 on enhancer regions was crucial for regulating the pausing release of a subset of genes.27 They found that JMJD6 bound to the C-terminus of Cdk9 and was co-recruited with 7SK snRNP to enhancers of »1022genes, where JMJD6 removed the cap structure of 7SK RNA to induce its degradation, reducing the stability of 7SK snRNP and promoting the on siterelease ofP-TEFb.27 

Another example ofon-siterelease of P-TEFb by remodeling 7SK RNA is DDX21*.28

 DDX21 is a DEAD-box RNA helicase capable of unwinding RNA in ATP-dependent manner.  It binds to 7SK RNA and, as a component of 7SK snRNP, is recruited to the promoters of genes encoding snoRNAs and ribosomal proteins. (Comment: DDX21 is SARS2 CoV  N proein interaction protein)
Both in vitro and in vivo assays indicate that DDX21 can release P-TEFb from 7SK snRNP through remodeling the secondary structure of 7SK RNA, allowing the transcription elongation of target genes.28 

In addition to remodeling 7SK RNA, PPM1G has been shown capable of releasing P-TEFbon-siteby modifying T-loop of Cdk9.29 
PPM1G is a protein phosphatase and is recruited to promoters by transcription factor NF-kB and HIV-encoded Tat protein.29,30
 By dephosphorylating T186ph of Cdk9, PPM1G disrupts the 7SK snRNPon siteto release P-TEFb to promoters.29 
Besides protein factors, PSA eRNA (an androgenreceptor-regulated enhancer RNA) has also been implicated in the disassembly of 7SK snRNP and the pause release of »674 genes.31
 In this case, PSA eRNAforms a secondary structure that is highly similar to the 30-end of 7SK RNA. PSA eRNA can then compete with 7SK for binding to Cyclin T1 subunit of P-TEFb, extracting P-TEFb out from 7SK snRNPon-site.31 

Taken together, the major feature of the non-canonical model is the loading of whole inactive 7SK snRNP complex, not active P-TEFb, on  to the promoter or enhancer regions of target genes. Although the on-siterelease of P-TEFb from 7SK snRNP
seems not as strict as in the canonical model, the diverseon-siteP-TEFb release mechanisms, nevertheless, may lend cells the ability to accommodate the transcriptional needs in response to diverse challenges. Moreover,on-siteactivation enables 7SK snRNP to release P-TEFb in proximity to the paused Pol II, allowing the quick response to various stimulations. 

Whether the two recruitment models can be reconciled with each other in cells?
 Given that both canonical and noncanonical mechanisms play roles in recruitment of P-TEFb in eukaryotic cells, it raises an intriguing question: Whether the two mechanisms can be reconciled with each other in cells under basal condition or after stimulation.

 Of interest, Fus Lab found that SR protein SRSF2 not only interacted with 7SK snRNP, but also associated with active P-TEFb recruitment factor Brd4.*26 
They showed that RNAi depletion of SRSF2 could remarkably reduce the recruitment of P-TEFb, but did not affect the promoter occupancy of HEXIM1 and Brd4.While depletion of Brd4 significantly reduced the promoter recruitment of both SRSF2 and P-TEFb, it had no effect on the promoter enrichment of HEXIM1.26 

These data raise a possibility that while ESE RNAinduces theon-siterelease of SRSF2 and P-TEFbfrom 7SK snRNP, SRSF2 interacts with P-TEFb and presents itself, together with P-TEFb, to Brd4. Then, Brd4 recruits P-TEFb to Spt5 subunit of DSIF via there cruitment pathway consisting of Med1, Med23 and Tat-SF1. In this way, SRSF2 connects two recruitment mechanisms together to accommodate the transcription needs even under the basal state.

 Another case is RelA subunit of NF-kB transcription factor. Brd4 has been shown to bind to NF-kB via interaction with acetylated-K310 of RelA in response to TNFa stimulation.19 This binding facilitates the recruitment of P-TEFb to the promoters of NF-kB target genes, including IL-8.
 On the other hand, 7SK snRNP is shown to associate with the IL-8 promoter. 

Upon TNFa stimulation, RelA can recruit PPM1G to IL-8 promoter, where PPM1G induces the release of P-TEFb from 7SK snRNP by dephosphorylating T-loop of Cdk9. Depletion of PPM1G results in the enrichment of HEXIM1 and LARP7* on IL-8 promoter but the decrease of P-TEFb in IL-8 gene body.29,30

 Combining these reported data, it is possible that theRelA-bound Brd4* might function as areceptorto accept the PPM1G-released P-TEFb and then recruits the P-TEFb to Spt5 of DSIF. Hence, RelA might play a role in co-ordinating the two recruitment mechanisms upon stimulation.

 Perspectives
 Over the past decade, our understanding on transcription elongation has been continuously undated. While the active P-TEFb has been thought to be the major form being recruited to promoters of target genes, recent advances indicate that the inactive 7SK snRNP can be the another choice to be deposited to promoters. However, several points still remain to be addressed.
One intriguing question is whether these two recruitment mechanisms are reconciled with each other in cells. Although the above-mentioned examples imply this possibility, it apparently needs direct evidence. Another point is that although KAP1 has been shown capable of recruiting 7SK snRNP to promoters of global genes, how the promoter-associated 7SK snRNP selectively releases its P-TEFb at promoter or enhancer regions that belong to distinct signal pathways is still unclear. 
Similarly, for the canonical model, how the active P-TEFb is specifically delivered to the target promoters in response to a given stimulation is murky. Finally, it has been widely accepted that the signal-dependent dephosphorylation at T186ph of Cdk9 T-loop by protein phosphatase, either off chromatin or on promoters, is key for P-TEFb release from 7SK snRNP. Since phosphorylation of T186 is of key importance for P-TEFbs kinase activity, the rephosphorylation of T186 is necessary for recovering P-TEFbs activity. 
However, how the dephosphorylated T186 of Cdk9 is rephosphorylated again remains to be investigated. Collectively, although current studies have identified different mechanisms for the recruitment of P-TEFb to promoters for pause release, there are still many unanswered questions. Future studies on thisfield should address the inducible recruitment and activation of P-TEFb.
 Disclosure of potential conflicts of interest
 No potential conflicts of interest were disclosed. 
Acknowledgments  We thank D. Feng and X. Lu for critical reading of themanuscript.